Aims: To evaluate the impact of bivalirudin versus heparin on efficacy and safety outcomes of ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) and to explore the impact of differential use (bailout vs. routine) of glycoprotein IIb/IIIa inhibitors (GPI). Methods and Results: Five randomized controlled trials encompassing 10,350 patients were included. Primary efficacy and safety endpoints were all-cause death and major bleeding, respectively. All-cause death at 30 days did not significantly differ with bivalirudin compared to heparin (odds ratio (OR) 0.97, 95% confidence interval (CI) 0.74-1.28; P=0.84). Major bleeding was significantly reduced by bivalirudin compared to heparin (OR 0.58, 95% CI 0.40-0.85; P=0.005). Bivalirudin use was associated with non-significantly different rates of 30-day definite stent thrombosis (ST) (OR 1.71, 95% CI 0.84-3.49; P=0.14), albeit with higher rates of acute ST (OR 3.55, 95% CI 1.67-7.56; P=0.001) and non-significantly different rates of subacute ST (OR 0.86, 95% CI 0.46-1.61; P=0.64). There were non-significant differences in the 30-day rates of reinfarction (OR 1.47, 95% CI 0.94-2.30; P=0.10) and cardiovascular death (OR 0.76, 95% CI 0.56-1.02; P=0.07). There were no significant interactions between bailout versus routine GPI use in the heparin arm for any of the safety or efficacy outcomes (all P interaction >0.10). Conclusions: Bivalirudin compared with heparin was associated with comparable 30-day rates of mortality with reduced major bleeding, at the price of an increased risk of acute ST, with non-significant differences in the overall 30-day rates of ST and reinfarction. Intended use of GPI in the heparin arm did not significantly modify the treatment effects of bivalirudin. Given the important differences between trials, as well as evolution in technique and adjunct pharmacotherapy, further randomized trials are warranted to discriminate whether there are substantial safety and efficacy differences between these agents during primary PCI in STEMI.
Introduction
According to European and US guidelines, primary percutaneous coronary intervention (PCI) is the standard of care for patients with ST-segment elevation myocardial infarction (STEMI). 1, 2 Among anticoagulation alternatives to support PCI, the direct antithrombin inhibitor bivalirudin was provided with a class I recommendation with level of evidence B based on data from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. 3, 4 In HORIZONS-AMI, bivalirudin reduced major bleeding at 30 days and cardiovascular mortality at 3 years compared with unfractionated heparin and routine use of a glycoprotein IIb/IIIa inhibitor (GPI), but increased the rates of acute stent thrombosis (ST).
PCI practice for STEMI has evolved in recent years, with more frequent pre-hospital initiation of antithrombotic treatment, widespread use of radial access, introduction of potent platelet P2Y 12 inhibitors (prasugrel, ticagrelor), and use of GPI restricted to bailout situations at selected centers. These changes were incorporated in the European Ambulance Acute Coronary Syndrome Angiography; (EUROMAX) trial, which demonstrated consistent results with HORIZONS-AMI. [5] [6] [7] [8] Subsequently, conflicting results from three additional randomized controlled trials (RCTs) of bivalirudin versus heparin in STEMI have been published and/or presented at major cardiovascular congresses, [9] [10] [11] with one single-center trial 11 raising concerns regarding the risk-benefit profile of bivalirudin compared with heparin monotherapy, leading to a downgrade of the recommendation for bivalirudin in primary PCI (from I to IIa) in the recently published European guidelines for myocardial revascularization. 12 Following these events, contrary results were reported from a large multicenter trial reconfirming the safety benefit of bivalirudin compared to heparin monotherapy, with similar rates of adverse ischemic events at 30 days and 1 year. 9 The manner in which GPI were used in the heparin arm (whether routine and/or for bailout only) may be an important modifying factor when interpreting the risk-benefit ratio of bivalirudin. Two meta-analyses of RCTs conducted across the broad spectrum of PCI (elective and acute coronary syndromes) concluded that bivalirudin, as compared to heparin without planned GPI use, reduces the risk of major bleeding at the expense of a higher risk of acute ST. 13, 14 However, those meta-analyses did not have STEMI as a primary focus and did not include the full dataset from the recently presented large-scale Bivalirudin in Acute Myocardial Infarction vs. Glycoprotein IIb/IIIa and Heparin: a Randomised Controlled Trial (BRIGHT), 9 including ST and long-term outcomes. In addition, the potential modifying effect of different GPI use strategies in primary PCI RCTs of bivalirudin has not fully been examined. We therefore performed an updated meta-analysis of RCTs to evaluate the impact of bivalirudin on efficacy and safety outcomes of patients with STEMI undergoing primary PCI compared to heparin with or without routine GPI use.
Methods
The study was designed in compliance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) standards. 15 Full description of the study methodology is provided in the Online Supplement. Briefly, the analysis was restricted to studies published or presented at a major cardiovascular meeting through September 2014 that met all the following inclusion criteria: randomized trial of bivalirudin versus heparin; study population of patients with acute myocardial infarction (at least 85% STEMI) undergoing PCI; follow-up outcomes reported for at least 30 days. The primary efficacy and safety endpoints were the 30-day incidences of all-cause death and protocoldefined major bleeding, respectively.
Results

Search results and study details
The initial search strategy identified 300 citations, of which 12 were retrieved for full text review. Five trials encompassing a total of 10,350 patients met all inclusion criteria and had no exclusion criteria ( Figure 1 ). Study details and related interventions are provided in the Online Supplement and in Supplementary Table S1 . The mean age of patients was 61 years. Seventy-seven per cent were men, 16% presented with diabetes mellitus and 44% were treated with radial access ( Supplementary Table S2 ).
Thirty-day results
All trials reported 30-day all-cause death, reinfarction, stroke, revascularization, definite ST and major bleeding rates. Four trials reported 30-day cardiovascular mortality and definite or probable ST (which was further classified as acute (<24 hours) and subacute (1-30 days)).
The pooled data showed no significant differences in allcause mortality (primary efficacy outcome) with bivalirudin versus heparin (2.8% vs. 2.7%, odds ratio (OR) 0.97 (0.74-1.28); P=0.84; Supplementary Table S3 , Figure 2) , with low heterogeneity (I 2 =18%), no asymmetry in the funnel plot, and no systematic bias apparent across studies (Begg's test P=0.62). Removal of individual studies did not significantly influence the point estimate ( Supplementary Table S4 ). There was no significant difference in 30-day cardiovascular mortality with bivalirudin compared to heparin (2.0% vs. 2.5%, OR 0.76 (0.56-1.02); P=0.07; Supplementary Table  S3 , Figure 3 ), nor heterogeneity (I 2 =0), evidence of asymmetry in the funnel plot, or systematic bias across studies (Begg's test P=0. 17) . The magnitude of the point estimate for cardiovascular mortality was influenced by the HORIZONS-AMI trial ( Supplementary Table S4 ).
Definitions of reinfarction used across studies are described in Supplementary Table S5 . There was no significant difference in 30-day reinfarction with bivalirudin compared to heparin (1.9% vs. 1.2%, OR 1.47 (0.94-2.30); P=0.10; Supplementary Table S3 , Figure 3 ), with mild heterogeneity (I 2 =37%) and no evidence of asymmetry in the funnel plot or systematic bias across studies (Begg's test P=0.62). Removal of HEAT-PPCI or EUROMAX reduced the magnitude of the point estimate ( Supplementary Table S4 ).
There was no significant difference in 30-day stroke with bivalirudin compared to heparin (0.8% vs. 0.9%, OR 0.87 (0.56-1.37); P=0.55; Supplementary Table S3 , Figure  3 ), with no evidence of heterogeneity (I 2 =0), asymmetry in the funnel plot, or systematic bias apparent across studies (Begg's test P=0. 14) . None of the studies unduly influenced the point estimate ( Supplementary Table S4 ).
There was no significant difference in 30-day revascularization with bivalirudin compared to heparin (2.4% vs. 1.6%, OR 1.46 (0.95-2.25); P=0.09; Supplementary Table  S3 , Figure 2 ), with mild heterogeneity (I 2 =45%) and no evidence of asymmetry in the funnel plot or systematic bias across studies (Begg's test P=0.62). Removal of HEAT-PPCI reduced the magnitude of the point estimate ( Supplementary Table S4 ).
There was no significant difference in 30-day definite (1.9% vs. 1.0%, OR 1.71 (0.84-3.46); P=0.14; Supplementary  Table S3 , Figure 4 ) and definite or probable ST (2.1% vs. 1.2%, OR 1.77 (0.84-2.73); P=0. 13 ; Supplementary Table  S3 , Figure 4 ) with bivalirudin compared to heparin. The risk of acute ST was significantly higher with bivalirudin (1.4% vs. 0.4%, OR 3.55 (1.67-7.56); P=0.001; Supplementary  Table S3 , Figure 4 ), with no significant differences in the risk of subacute ST (0.8% vs. 0.8%, OR 0.86 (0.46-1.61); P=0.64; Supplementary Table S3 , Figure 4 ). Moderate heterogeneity was observed for definite ST and definite or probable ST and mild heterogeneity for acute and subacute ST. There was no asymmetry in the funnel plot for any of the ST endpoints or systematic bias across studies (Begg's test P=NS for all endpoints). The point estimates of definite ST and definite or probable ST became significant after the exclusion of BRIGHT, whereas the point estimate of acute ST became non-significant after the exclusion of HORIZONS-AMI or HEAT-PPCI. None of the studies was found to influence the point estimate for subacute ST ( Supplementary Table S4 ). The OR for acute ST was 1.98 (0.17-23.50; P=0.59) in analyses restricted to studies with routine post-PCI bivalirudin infusion and 4.04 (2.01-8.11; P<0.0001) in analyses restricted to studies with no routine post-PCI bivalirudin infusion (P interaction =0.59; Table 1 ).
Definitions of protocol-defined major bleeding used across studies are described in Supplementary Table S6 . The pooled data showed a significant reduction in major bleeding with bivalirudin (3.9% vs. 7.2%, OR 0.58 (0.40-0.85); P=0.005; Supplementary Table S3 , Figure 5 ), with moderate heterogeneity (I 2 =64%), and no evidence of asymmetry in the funnel plot or systematic bias across studies (Begg's test P=1.00). The reduction in major bleeding with bivalirudin persisted if BARC 1-5 bleeding in BRIGHT (the study definition) was replaced with BARC 2-5 bleeding (OR 0.57 (0.37-0.88); P=0.01) or BARC 3-5 bleeding (OR 0.61 (0.40-0.92); P=0.02). Although the risk of major bleeding remained numerically lower with bivalirudin, removal of HORIZONS-AMI, EUROMAX or BRIGHT one at a time resulted in loss of significance for the point estimate, and removal of HEAT-PPCI substantially strengthened the point estimate ( Supplementary Table S4 ).
GPI interaction
There were no significant interactions between the pooled point estimate for any safety or efficacy endpoint of the meta-analysis and the modality of GPI use in the heparin arm (all P interaction >0.10; Figure 6 ). The OR for major bleeding was 0.64 (0.33-1.23) in analyses restricted to studies with bailout GPI use and 0.49 (0.36-0.67) in analyses restricted to studies with routine GPI use (P interaction =0.49; Figure 6 ).
Long-term results
BRIGHT reported 1-year event rates and HORIZONS-AMI reported 3-year event rates. The outcomes of the pooled analysis of the two trials at the longest available follow up are illustrated in Supplementary Table S7 . Bivalirudin was associated with a reduced risk of all-cause mortality compared with heparin (OR 0.77 (0.61-0.99); P=0.04), with no heterogeneity (I 2 =0). Conversely, there were no significant differences in reinfarction (OR 0.81 (0.62-1.06); P=0.12; I 2 =5), stroke (OR 0.78 (0.51-1.22); P=0.28; I 2 =0), revascularization (OR 1.21 (1.00-1.47); P=0.09; I 2 =0), and definite or probable ST (OR 0.88 (0.65-1.20); P=0.43; I 2 =0). There was a trend towards less bleeding with bivalirudin (OR 0.50 (0.24-1.03); P=0.06), with moderate heterogeneity (I 2 =54).
Discussion
The major findings from this meta-analysis of five randomized trials are summarized as follows. First, in patients with STEMI undergoing primary PCI, bivalirudin reduced the 30-day risk of major bleeding with similar mortality compared with heparin. Second, bivalirudin was associated with a greater rate of ST within the first 24 hours of the procedure. Third, these results were consistent whether the control arm was heparin with the routine use of GPI or heparin alone with provisional GPI reserved for bailout. Fourth, mild-to-moderate heterogeneity was observed for many of the endpoints and the point estimates for several of the major outcomes were sensitive to the removal of single studies. The results of this meta-analysis should therefore be interpreted with caution given the differences between the included trials.
In the HORIZONS-AMI trial, bivalirudin resulted in reduced rates of major and minor bleeding compared to heparin plus routine GPI in STEMI, with reduced cardiovascular and all-cause mortality at 30 days and 3 years. 3, 4 HORIZONS-AMI was also the first trial to report increased rates of acute ST with bivalirudin, a finding subsequently observed in EUROMAX and HEAT-PPCI, but not in BRIGHT or BRAVE-4. In no trial was ST increased with bivalirudin after 24 hours. Differences between trials may explain the interstudy variability in acute ST risk with bivalirudin. Bivalirudin has a short half-life, and the rapid door-to-balloon and procedure times achieved in contemporary trials may have offered minimal anti-thrombin exposure from bivalirudin if the drug was used during the procedure only. In this regard the use of a post-PCI bivalirudin infusion varied across studies, from being not routinely used in HORIZONS-AMI, HEAT-PPCI and BRAVE-4, to being used in most or all patients in EUROMAX (4:1 low-dose:high-dose at operator discretion) and BRIGHT (low-dose). In a post-hoc observation from EUROMAX, the use of a post-procedure bivalirudin infusion for median 4.5 hours at the PCI dose eliminated the acute ST risk after primary PCI. 16 In BRIGHT, 9 the use of a routine low-dose bivalirudin infusion for 4 hours was also associated with the absence of acute ST risk. In the present meta-analysis a significant interaction was not present between the use of a post-PCI bivalirudin infusion and the risk of acute ST, although the risk of acute ST with bivalirudin was significant in analyses restricted to studies in which routine infusion was used, and non-significant in analyses restricted to studies without routine infusion. The routine use of prasugrel may also have reduced the rate of acute ST in BRAVE-4, although given the delayed absorption of P2Y 12 inhibitors in STEMI 17, 18 and the lack of a similar effect in EUROMAX and HEAT-PPCI, this finding may be due to chance. Pending further studies on the association with newer P2Y 12 inhibitors in STEMI, a 4-hour post-PCI infusion of bivalirudin seems prudent, and was not associated with increased bleeding in either BRIGHT or EUROMAX. Extending the bivalirudin infusion post-procedure may overcome the theoretical treatment gap between the rapid offset of antithrombin therapy with bivalirudin and the slow onset of therapeutic efficacy of antiplatelet drugs in the setting of STEMI. 19 The impact of a prolonged low-dose bivalirudin infusion on the risk-benefit profile of bivalirudin is under further investigation in the Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX) trial. 20 Other important differences were present between the trials in the present (and previous) meta-analyses that may affect their interpretation. First, radial intervention, which may reduce major bleeding rates, was frequent in EUROMAX, BRIGHT and HEAT-PPCI, but uncommon in HORIZONS-AMI and BRAVE-4. Second, the potent P2Y 12 inhibitors prasugrel or ticagrelor were frequently used in EUROMAX, HEAT-PPCI and BRAVE-4, but not in HORIZONS-AMI or BRIGHT. Third, in EUROMAX, GPI use in the heparin arm was left to the operator's discretion, but no interaction was present between the treatment effect of bivalirudin and routine versus provisional GPI use. [5] [6] [7] Fourth, patients were randomly assigned early during transfer for primary PCI in EUROMAX, which avoided a possible confounding effect of pre-randomization heparin as noted in HORIZONS-AMI. Fifth, in the three-arm randomized BRIGHT trial, bivalirudin was found to reduce the risk of bleeding compared with heparin monotherapy or heparin plus routine GPI, 9 while in HEAT-PPCI, GPI was restricted to bailout use in both the bivalirudin and heparin groups, and an increased risk of acute ST was observed with bivalirudin without a reduction in bleeding. 11 In this regard it should be highlighted that the heparin dose used in heparin monotherapy-treated patients ranged from 70 U/kg in HEAT-PPCI to 100 U/kg in EUROMAX and BRIGHT. Bivalirudin was associated with reduced major bleeding in Figure 6 . Outcomes of the meta-analysis stratified by GPI use in the heparin arm. Random-effects odds ratio and 95% confidence interval are reported according to GPI use (bailout vs. routine) in the heparin arm. Interaction values for subgroup differences between studies with routine GPI use in the heparin arm and studies with bailout GPI use in the heparin arm are reported. For the purpose of this analysis, the heparin arms of the BRIGHT trial were considered separately in the comparison versus the bivalirudin group.
CV: cardiovascular; GPI: glycoprotein IIb/IIIa inhibitors; OR: odds ratio; RE: random effects; ST: stent thrombosis. EUROMAX and BRIGHT (the studies using a high dose in patients on heparin monotherapy), but not in HEAT-PPCI (which used a lower dose). Sixth, the BRAVE-4 trial was stopped prematurely and showed no differences in bleeding and ischemic endpoints between patients allocated to bivalirudin plus prasugrel compared to heparin plus clopidogrel. 10 The fact that both the antithrombin and P2Y 12 antagonist were randomized in this trial makes the findings difficult to interpret. Finally, all the trials were multicenter except HEAT-PPCI, which was unique in randomly assigning a near all-comers population, although lacking the external validity and generalizability of multicenter trials. 21 In our analysis bivalirudin decreased major bleeding. Although this benefit was numerically greater in trials in which GPI use was routine rather than reserved for bailout, the interaction term for GPI use and treatment effect was not statistically significant, consistent with the BRIGHT results and the post-hoc analysis from EUROMAX. 7 These data thus suggest that bivalirudin reduces major bleeding in patients with STEMI undergoing primary PCI compared to heparin alone or heparin plus routine GPI. The significantly higher risk of acute ST with bivalirudin, with no difference in subacute ST, was also independent of GPI use (routine vs. provisional) in the heparin arm. The increased risk of acute ST likely drove trends toward increased 30-day rates of reinfarction and revascularization with bivalirudin treatment as well. No such trends were observed in BRIGHT or BRAVE-4, however, given the absence of an acute ST risk with bivalirudin. Mitigating the acute ST propensity with bivalirudin (e.g. with a 4-hour post-PCI infusion, if proved to be effective) would clearly improve its overall risk-benefit ratio.
Considering the net effects of ischemic and bleeding complications is important. In this regard, the use of bivalirudin rather than heparin (with or without GPI) was associated with a trend towards reduced 30-day cardiovascular mortality, with comparable all-cause mortality. A significant reduction in all-cause mortality was found at long term in the pooled analysis of HORIZONS-AMI and BRIGHT, the only studies reporting a 1-year or longer follow-up. Given the differences in study design and adjunctive therapies between trials it is clear that additional large-scale, adequately powered RCTs (with long-term follow-up) are required to resolve remaining uncertainties.
The definition of reinfarction varied substantially between trials, and the non-significant trend for greater reinfarction seen with bivalirudin was decreased after individually removing EUROMAX or HEAT-PPCI. In this regard these trials stand out in that the bailout rates of GPI were particularly high in the heparin-only arms (25.4% and 13.5%, respectively) compared to the others, a practice of uncertain clinical utility. In addition, door-to-balloon times in HEAT-PPCI were less than 30 minutes (leading to a very short bivalirudin infusion) and the activated clotting times were substantially lower than usually seen with bivalirudin, but not with heparin (a finding difficult to interpret, however, given the use of a non-standard assay). The definitions of protocol-defined major bleeding also varied substantially between trials, with BRIGHT pre-specifying all bleeding as the major safety endpoint. However, bivalirudin use was still associated with reduced rates of major bleeding when only BARC 2-5 or 3-5 bleeding rates from BRIGHT were considered in the meta-analysis.
Study limitations
The results of this meta-analysis are subject to the limitations and differences of the original included studies themselves. Variation in study design (Supplementary Tables S1 and S2), endpoint definitions (Supplementary Tables S5, S6 and S8) and publication bias are limitations of all meta-analyses. All included studies share the limitation of an open-label design. Randomization in EUROMAX was not stratified by intended routine versus bailout GPI use, introducing the possibility of imbalances between groups, although in a pre-specified multivariable analysis the relative effects of bivalirudin were not affected by GPI use pattern. The BRIGHT trial included 12% of patients with non-STEMI; outcomes of the STEMI cohort have not been separately presented, with the exception of ST. Moreover, data from BRIGHT are currently unpublished. The limitations inherent in the single-center HEAT-PPCI design have been discussed, as have the implications of the randomization scheme and early termination of BRAVE-4. In this regard several of the results were sensitive to the HEAT-PPCI results, whereas omitting BRAVE-4 did not significantly change any of the point estimates in our meta-analysis. In addition, the trials varied markedly in the use of pre-randomization heparin and study drug, radial artery access, potent P2Y 12 inhibitors, post-PCI bivalirudin and heparin infusions or low molecular-weight heparin use, and other factors that could not be completely accounted for in the present analysis (Online Supplement). Finally, follow-up beyond 30 days was available for only two of the studies. The 1-3 year data from HORIZONS-AMI and BRIGHT suggest a sustained or improving risk-benefit profile of bivalirudin over time, but more data are needed in this regard.
Conclusions
In this updated meta-analysis from five RCTs, bivalirudin was found to reduce the 30-day rates of major bleeding with similar survival compared to heparin monotherapy or heparin plus GPI in patients with STEMI undergoing primary PCI. Bivalirudin was associated with an increased risk of acute ST, but not subacute or total ST. Non-significant trends were present for an increased risk of reinfarction and repeat revascularization with bivalirudin, but also of reduced cardiovascular mortality, compared with heparin. Routine versus bailout GPI use in the heparin arm did not significantly modify the riskbenefit ratio of bivalirudin compared with heparin for any of these safety and efficacy endpoints. Bivalirudin was associated with improved long-term survival based on the available data from two studies. Given differences between the included trials, however, and evolution in technique and adjunct pharmacotherapy, additional large-scale randomized trials (including embedded cost-effectiveness assessment) with long-term follow-up are warranted to determine whether there are clinically relevant differences between bivalirudin and heparin with or without routine GPI in patients with STEMI undergoing primary PCI.
